Competition & Peer Data API & CSV Delivery Connect to AI Assistant via MCP

China Pharma Holdings Inc's Competitiveness

A competitive positioning analysis and financial ratio benchmarking of China Pharma Holdings Inc (CPHI) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.

Peer Data As of Q2 2026
Competitors Tracked
-
Publicly traded peers
Peer Group Market Share
100.00 %
vs 100.00 % a year ago
Revenue Growth Y/Y
-7.55 %
Q2 2026
Net Margin
-153.76 %
Q2 2026

Key Findings: China Pharma Holdings Inc vs Its Competitors

  • TTM: Trailing 12-month revenue of 4M vs -M combined for tracked competitors (100.0% combined share).
  • Trending: Latest-quarter revenue run-rate is decelerating (-3.1% annualized vs trailing 12 months).
  • Scale: China Pharma Holdings Inc ranks #363 of 544 companies by market capitalization in the Major Pharmaceutical Preparations industry, holding 0.0% of industry market cap.
  • Peer revenue share: China Pharma Holdings Inc accounted for 100.0% of combined revenue among its tracked peer group, up from 100.0% a year earlier.

Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).

CPHI Sales vs. its Competitors, Q2 2026

China Pharma Holdings Inc generated 100.00 % of the combined sales of its peer group, up from 100.00 % a year earlier.

API endpoints for this dataset
https://api.csimarket.com/api/v1/companies/CPHI/competitors
https://api.csimarket.com/api/v1/companies/CPHI/relationships
https://api.csimarket.com/api/v1/companies/CPHI/similar
Programmatic access for models, analytics, and integration workflows.

For context: the Major Pharmaceutical Preparations industry grew revenue 9.0% year over year, combined, vs -7.6% for China Pharma Holdings Inc. China Pharma Holdings Inc's share of combined industry revenue moved from 0.00% to 0.00%, a gain of 0.00 percentage points.

China Pharma Holdings Inc's Competitor Quality Breadth

Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).

Entity Profitable Expanding Above Industry Growth Distressed
China Pharma Holdings Inc No No No Yes
Similar-Size Competitors (10) 17% 25% 25% 78%
Similar Growth & Profitability (8) 0.00 % (0 of 8) 50.00 % (4 of 8) 25.00 % (2 of 8) 25.00 % (2 of 8)

Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.

Market Share of the Peer Group, Q2 2026

100%market share
  • China Pharma Holdings Inc100.0%
  • Competitors combined0.0%

Share of combined quarterly revenue of China Pharma Holdings Inc and its 0 tracked competitors.

See China Pharma Holdings Inc's full market share breakdown »

CPHI Stock Performance relative to its Competitors

CPHI Competitors (weighted) Percent change over the selected range

China Pharma Holdings Inc's Share Price Performance vs Peer Groups

Trailing 12-month total share price return, and the share of each group that outperformed the U.S.A. 500 over the same period. Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC.
11.1%beat U.S.A. 500
Similar-Size
(1 of 9)
33.3%beat U.S.A. 500
Similar Growth & Profitability
(1 of 3)
Entity TTM Share Price Return
(group: median)
vs U.S.A. 500
China Pharma Holdings Inc -66.50 % Underperformed
Competitors combined (0) 40.4% 63.2%
High-Confidence Competitors (0) 40.4% 63.2%
Similar-Size Competitors (9) 40.4% 63.2%
Similar Growth & Profitability (3) 40.4% 63.2%
Peer Group Share Price Returns

TTM share price return and U.S.A. 500 outperformance for China Pharma Holdings Inc's competitor groups requires a Commercial License.

Source: CSIMarket API (daily market-structure computation). Outperformance is trailing-12-month total return vs the U.S.A. 500 over the same window, not risk-adjusted.

CPHI Stock Performance relative to Similar-Size Competitors

CPHI Similar-Size Competitors (equal-weighted, 10) Percent change over the selected range

CPHI Stock Performance relative to Similar Growth & Profitability Competitors

CPHI Similar Growth & Profitability Competitors (equal-weighted, 8) Percent change over the selected range

China Pharma Holdings Inc's Comment on Competition and Industry Peers

Helpson operates in the highly fragmented Chinese pharmaceutical industry, which includes both local and international companies producing similar or substitute pharmaceutical products. The company leverages over 20 years of product development experience, a market-oriented product portfolio, diversified GMP-certified delivery systems, a national sales network, and established relationships with hospitals and clinics. Helpson faces competition from firms with potentially greater capital, research and development resources, manufacturing and marketing capabilities, and industry experience. The company’s profitability is subject to risks such as increased competition, price pressures, and the emergence of new or substitute products that may offer improved efficacy, lower costs, or additional benefits.

China Pharma Holdings Inc's Competitors Named by the Company

Competitive relationships identified from SEC filings and corroborating sources, each with a basis and confidence.
Competitor Basis Confidence Active Sources
Helpson Named by the company 85% 2022 to 2026 3
Competitor Evidence Detail

Filing basis, confidence, active dates and source counts for China Pharma Holdings Inc's named competitors require a Commercial License.

Methodology: relationships are extracted from SEC filings (named-competitor disclosures) and corroborating sources. Named by the company = explicitly disclosed as a competitor; Inferred = derived from corroborating signals. Confidence reflects evidence strength.

Get the full CSIMarket dataset: Subscribe API License